4,806 Shares in Emergent BioSolutions (EBS) Purchased by Two Sigma Investments LP

Two Sigma Investments LP acquired a new position in Emergent BioSolutions (NYSE:EBS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,806 shares of the biopharmaceutical company’s stock, valued at approximately $223,000.

Several other institutional investors have also bought and sold shares of the company. Meeder Asset Management Inc. boosted its position in shares of Emergent BioSolutions by 29.8% in the 4th quarter. Meeder Asset Management Inc. now owns 6,141 shares of the biopharmaceutical company’s stock worth $285,000 after purchasing an additional 1,409 shares in the last quarter. Swiss National Bank boosted its position in shares of Emergent BioSolutions by 3.2% in the 4th quarter. Swiss National Bank now owns 58,700 shares of the biopharmaceutical company’s stock worth $2,728,000 after purchasing an additional 1,800 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its position in shares of Emergent BioSolutions by 11.9% in the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 20,680 shares of the biopharmaceutical company’s stock worth $835,000 after purchasing an additional 2,200 shares in the last quarter. Martingale Asset Management L P boosted its position in shares of Emergent BioSolutions by 12.0% in the 4th quarter. Martingale Asset Management L P now owns 20,611 shares of the biopharmaceutical company’s stock worth $958,000 after purchasing an additional 2,205 shares in the last quarter. Finally, Allianz Asset Management GmbH boosted its position in shares of Emergent BioSolutions by 3.3% in the 4th quarter. Allianz Asset Management GmbH now owns 70,130 shares of the biopharmaceutical company’s stock worth $3,259,000 after purchasing an additional 2,217 shares in the last quarter. 81.57% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

A number of research firms have recently weighed in on EBS. Goldman Sachs began coverage on Emergent BioSolutions in a research report on Wednesday, January 24th. They issued a “neutral” rating and a $55.00 price objective for the company. Zacks Investment Research raised Emergent BioSolutions from a “hold” rating to a “strong-buy” rating and set a $53.00 price objective for the company in a research report on Tuesday, January 2nd. Chardan Capital raised their price objective on Emergent BioSolutions from $47.00 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, January 16th. ValuEngine raised Emergent BioSolutions from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Finally, Singular Research raised their price objective on Emergent BioSolutions from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Emergent BioSolutions has an average rating of “Buy” and an average target price of $52.80.

Shares of EBS stock opened at $54.37 on Friday. The firm has a market capitalization of $2,726.16, a P/E ratio of 29.14, a PEG ratio of 1.07 and a beta of 1.29. The company has a quick ratio of 3.42, a current ratio of 4.85 and a debt-to-equity ratio of 0.01. Emergent BioSolutions has a 1 year low of $28.52 and a 1 year high of $55.91.

Emergent BioSolutions (NYSE:EBS) last issued its earnings results on Thursday, February 22nd. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.70 by $0.04. The company had revenue of $193.80 million during the quarter, compared to analyst estimates of $189.96 million. Emergent BioSolutions had a return on equity of 13.66% and a net margin of 14.73%. The firm’s quarterly revenue was up 27.8% on a year-over-year basis. During the same quarter last year, the business posted $0.74 EPS. analysts forecast that Emergent BioSolutions will post 2.33 EPS for the current fiscal year.

Emergent BioSolutions declared that its Board of Directors has initiated a share buyback program on Thursday, March 22nd that permits the company to repurchase $50.00 million in shares. This repurchase authorization permits the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

In related news, Director Ronald Richard sold 7,893 shares of the firm’s stock in a transaction on Tuesday, April 17th. The stock was sold at an average price of $55.00, for a total value of $434,115.00. Following the completion of the transaction, the director now owns 31,303 shares in the company, valued at approximately $1,721,665. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Adam Havey sold 1,898 shares of the firm’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $49.50, for a total value of $93,951.00. The disclosure for this sale can be found here. Insiders sold a total of 20,785 shares of company stock valued at $1,098,929 in the last 90 days. 16.50% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://ledgergazette.com/2018/04/20/4806-shares-in-emergent-biosolutions-ebs-purchased-by-two-sigma-investments-lp.html.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Institutional Ownership by Quarter for Emergent BioSolutions (NYSE:EBS)

Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply